495 related articles for article (PubMed ID: 17087947)
41. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
Leung WK; Ng EK; Chan FK; Chan WY; Chan KF; Auyeung AC; Lam CC; Lau JY; Sung JJ
Clin Cancer Res; 2006 Aug; 12(15):4766-72. PubMed ID: 16899628
[TBL] [Abstract][Full Text] [Related]
42. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Cole BF; Baron JA; Sandler RS; Haile RW; Ahnen DJ; Bresalier RS; McKeown-Eyssen G; Summers RW; Rothstein RI; Burke CA; Snover DC; Church TR; Allen JI; Robertson DJ; Beck GJ; Bond JH; Byers T; Mandel JS; Mott LA; Pearson LH; Barry EL; Rees JR; Marcon N; Saibil F; Ueland PM; Greenberg ER;
JAMA; 2007 Jun; 297(21):2351-9. PubMed ID: 17551129
[TBL] [Abstract][Full Text] [Related]
43. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Madigan D; Sigelman DW; Mayer JW; Furberg CD; Avorn J
Am Heart J; 2012 Aug; 164(2):186-93. PubMed ID: 22877803
[TBL] [Abstract][Full Text] [Related]
44. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
45. Colorectal adenoma characteristics as predictors of recurrence.
Bonithon-Kopp C; Piard F; Fenger C; Cabeza E; O'Morain C; Kronborg O; Faivre J;
Dis Colon Rectum; 2004 Mar; 47(3):323-33. PubMed ID: 14991494
[TBL] [Abstract][Full Text] [Related]
46. Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma.
Micheletto C; Tognella S; Guerriero M; Dal Negro R
Eur Ann Allergy Clin Immunol; 2006 Jan; 38(1):10-4. PubMed ID: 16544582
[TBL] [Abstract][Full Text] [Related]
47. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty.
van der Heide HJ; Rijnberg WJ; Van Sorge A; Van Kampen A; Schreurs BW
Acta Orthop; 2007 Feb; 78(1):90-4. PubMed ID: 17453398
[TBL] [Abstract][Full Text] [Related]
48. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
van der Veen WJ; van der Werf GT
Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
[TBL] [Abstract][Full Text] [Related]
49. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors.
Cottet V; Pariente A; Nalet B; Lafon J; Milan C; Olschwang S; Bonaiti-Pellié C; Faivre J; Bonithon-Kopp C;
Gastroenterology; 2007 Oct; 133(4):1086-92. PubMed ID: 17919484
[TBL] [Abstract][Full Text] [Related]
50. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow SH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez EM; Alberts DS; Lance P
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530656
[TBL] [Abstract][Full Text] [Related]
51. Risk of prostate cancer in a randomized clinical trial of calcium supplementation.
Baron JA; Beach M; Wallace K; Grau MV; Sandler RS; Mandel JS; Heber D; Greenberg ER
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):586-9. PubMed ID: 15767334
[TBL] [Abstract][Full Text] [Related]
52. Long-term risk of ischemic stroke associated with rofecoxib.
Afilalo J; Coussa-Charley MJ; Eisenberg MJ
Cardiovasc Drugs Ther; 2007 Apr; 21(2):117-20. PubMed ID: 17393291
[TBL] [Abstract][Full Text] [Related]
53. Prophylactic COX 2 inhibitor: an end to the Yom Kippur headache.
Drescher MJ; Elstein Y
Headache; 2006; 46(10):1487-91. PubMed ID: 17115981
[TBL] [Abstract][Full Text] [Related]
54. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
Andersohn F; Suissa S; Garbe E
Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
[TBL] [Abstract][Full Text] [Related]
55. Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Lekakis JP; Vamvakou G; Andreadou I; Ganiatsos G; Karatzis E; Protogerou A; Papaioannou T; Ikonomidis I; Papamichael C; Mavrikakis ME
Int J Cardiol; 2006 Oct; 112(3):359-66. PubMed ID: 16330117
[TBL] [Abstract][Full Text] [Related]
56. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis.
Wong M; Jiang BY; McNeill K; Farish S; Kirkham B; Chowienczyk P
Scand J Rheumatol; 2007; 36(4):265-9. PubMed ID: 17763203
[TBL] [Abstract][Full Text] [Related]
57. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
59. The patient's perspective on the recall of Vioxx.
Hawker GA; Katz JN; Solomon DH
J Rheumatol; 2006 Jun; 33(6):1082-8. PubMed ID: 16755654
[TBL] [Abstract][Full Text] [Related]
60. Sporadic duodenal adenoma and the association with colorectal neoplasia: a case-control study.
Ramsoekh D; van Leerdam ME; Dekker E; Ouwendijk RT; van Dekken H; Kuipers EJ
Am J Gastroenterol; 2008 Jun; 103(6):1505-9. PubMed ID: 18510617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
